LncRNA PART1 inhibits glioma proliferation and migration via miR-374b/SALL1 axis

Deng, Yongwen; Shu, Yu-Gao; Sun, Song

doi:10.1016/j.neuint.2022.105347

Cited by 13 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A growing number of studies has revealed intricate interactions via complex lnRNA-miRNA networks. LncRNA PART1 can suppress glioma proliferation and migration via miR-374b/SALL1 axis ( 95 ), LINC00689 can inhibit glioma tumorigenesis via the miR-526b-3p/IGF2BP1 axis ( 96 ), GAS5 can alter the EMT process, proliferation, migration, and invasion of glioma cells through miR-106b targeting PTEN ( 97 ). Other lnRNA-miRNA interactions have been implicated in resistance to glioma therapy resistance.…”

Section: Discussion With Biomarkersmentioning

confidence: 99%

Latest updates on cellular and molecular biomarkers of gliomas

et al. 2022

View full text Add to dashboard Cite

Gliomas are the most common central nervous system malignancies, compromising almost 80% of all brain tumors and is associated with significant mortality. The classification of gliomas has shifted from basic histological perspective to one that is based on molecular biomarkers. Treatment of this type of tumors consists currently of surgery, chemotherapy and radiation therapy. During the past years, there was a limited development of effective glioma diagnostics and therapeutics due to multiple factors including the presence of blood-brain barrier and the heterogeneity of this type of tumors. Currently, it is necessary to highlight the advantage of molecular diagnosis of gliomas to develop patient targeted therapies based on multiple oncogenic pathway. In this review, we will evaluate the development of cellular and molecular biomarkers for the diagnosis of gliomas and the impact of these diagnostic tools for better tailored and targeted therapies.

show abstract

Section: Discussion With Biomarkersmentioning

confidence: 99%

Latest updates on cellular and molecular biomarkers of gliomas

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Similarly, PART1 has a tumor suppressor role in glioma through sponging miR-190a-3p and inactivating PTEN/AKT signals ( Jin et al, 2020 ). Moreover, it can block carcinogenic process in glioma through modulation of miR-374b/SALL1 axis ( Deng et al, 2022 ). Tables 1 , 2 summarize the results of in vitro studies that reported up-regulation and down-regulation of PART1, respectively.…”

Section: Role Of Part1 In Cancersmentioning

confidence: 99%

“…Similar to in vitro studies, both tumor suppressor role and oncogenic role have been reported for PART1. Examples of the former type of function have been seen in animal models of cervical squamous cell carcinoma ( Liu et al, 2020 ), gastric cancer ( Han et al, 2020 ) and glioma ( Deng et al, 2022 ) where up-regulation of PART1 has resulted in reduction of tumor growth. Animal models of colorectal carcinoma ( Zhou et al, 2020a ), hepatocellular carcinoma ( Pu et al, 2020 ), lung cancer ( Zhu et al, 2019 ), oral squamous cell carcinoma ( Yu et al, 2021 ), ovarian cancer ( Li et al, 2022b ) and triple negative breast cancer ( Cruickshank et al, 2021 ).…”

Section: Role Of Part1 In Cancersmentioning

confidence: 99%

A review on the role of long non-coding RNA prostate androgen-regulated transcript 1 (PART1) in the etiology of different disorders

Ghafouri‐Fard

Harsij²,

Hussen³

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

LncRNA prostate androgen-regulated transcript 1 (PART1) is an important lncRNA in the carcinogenesis whose role has been firstly unraveled in prostate cancer. Expression of this lncRNA is activated by androgen in prostate cancer cells. In addition, this lncRNA has a role in the pathogenesis intervertebral disc degeneration, myocardial ischemia-reperfusion injury, osteoarthritis, osteoporosis and Parkinson’s disease. Diagnostic role of PART1 has been assessed in some types of cancers. Moreover, dysregulation of PART1 expression is regarded as a prognostic factor in a variety of cancers. The current review provides a concise but comprehensive summary of the role of PART1 in different cancers and non-malignant disorders.

show abstract

“…Accumulating evidence has shown that lncRNAs play pivotal roles in cancer cell proliferation, migration, apoptosis, and drug resistance (22)(23)(24)(25)(26)(27). Ewing sarcoma-associated transcript 1 (EWSAT1) is a lncRNA located between two protein-coding genes (NOX5 and GLCE) on chromosome 15.…”

Section: Introductionmentioning

confidence: 99%

LncRNA Inhibits the Viability of Triple-Negative Breast Cancer (TNBC) by Targeting the miR-330-5p/BCL2L2 Axis

Ye,

Fan,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) play important regulatory roles in the progression of kinds of cancers. However, the biological roles of most lncRNAs in breast cancer, especially TNBC, remain unclear. In this study, we investigated the functional of a novel lncRNA, named lncRNA EWSAT1, in the breast cancer and the underlying molecular mechanisms. EWSAT1 was significantly upregulated in the triple negative breast cancer (TNBC) tissues compared with adjacent normal tissues in the GEO databases. We verified the upregulated level of EWSAT1 in the TNBC patients’ serums compared with healthy serums, which also associated with clinical diagnosis. Bioinformatics analysis demonstrated that microRNA (miR)-330-5p was a potential target of SEAS1. Dual luciferase reporter assays confirmed that EWSAT1 functioned as a sponge for miR-330-5p, regulating the expression of BCL2L2. Moreover, RT-qPCR demonstrated that EWSAT1 negatively regulated the expression of miR-330-5p, and positively regulated the expression of BCL2L2 at transcription and protein level. CCK-8 demonstrated that EWSAT1 could inhibit the viability of TNBC cells. In conclusion, our studies find a functional lncRNA EWSAT1 in the TNBC, and reveal a novel pathway for TNBC treatment via EWSAT1/miR-330-5p/BCL2L2, and suggest EWSAT1 might be a potential biomarkers for TNBC diagnosis and therapeutic target for TNBC.

show abstract

LncRNA PART1 inhibits glioma proliferation and migration via miR-374b/SALL1 axis

Cited by 13 publications

References 34 publications

Latest updates on cellular and molecular biomarkers of gliomas

Latest updates on cellular and molecular biomarkers of gliomas

A review on the role of long non-coding RNA prostate androgen-regulated transcript 1 (PART1) in the etiology of different disorders

LncRNA Inhibits the Viability of Triple-Negative Breast Cancer (TNBC) by Targeting the miR-330-5p/BCL2L2 Axis

Contact Info

Product

Resources

About